YUKI LAB: KEY PUBLICATIONS 2019

2019

Volatile anesthetics isoflurane and sevoflurane directly target and attenuate Toll-like receptor 4 system. T, Koutsogiannaki S, Hou L, Bu W, Ohto U, Eckenhoff RG, Yokomizo T, Yuki K. FASEB J. 2019; 33(12): 14528-14541

 

Serpin B1 controls encephalitogenic T helper cells in neuroinflammation. L, Rao DA, Yuki K, Cooley J, Henderson LA, Johnsson AH, Kaiserman D, Gorman MP, Nigrovic PA, Bird PI, Becher B, Remold-O’Donnell E. Proc Natl Acad Sci USA. 2019; 116(41): 20635-20643

 

The volatile anesthetic sevoflurane reduces neutrophil apoptosis via Fas death domain-Fas-associated death domain interaction. S, Hou L, Babazada H, Okuno T, Blazon-Brown N, Soriano SG, Yokomizo T, Yuki K. FASEB J. 2019; 33(11): 12668-12679

 

The outcome of pediatric hematopoietic stem cell transplantation recipients requiring intensive care unit admission- A single center experience. Kwon R, Koutsogiannaki S, Staffa SJ, Yuki K. Transl Perioper Pain Med 2019; 6(3): 75-80

 

Volatile anesthetics affect macrophage phagocytosis. H, Matsunami E, Blazon-Brown N, Koutsogiannaki S, Hou L, Bu W, Babazada H, Odegard KC, Liu R, Eckenhoff RG, Yuki K. Plos One 2019; 14(5): e0216163

 

The use of volatile anesthetics as sedatives for acute respiratory distress syndrome. S, Shimaoka M, Yuki K. Trail Perioper Pain Med 2019; 6(2): 27-38

 

Volatile anesthetic attenuates phagocyte function and worsens bacterial loads in wounds. S, Bernier R, Tazawa K, Yuki K. J Surg Res 2019; 233: 323-330